scholarly journals Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma

Cancer ◽  
2004 ◽  
Vol 100 (3) ◽  
pp. 499-506 ◽  
Author(s):  
Francisco J. Esteva ◽  
Aysegul A. Sahin ◽  
Terry L. Smith ◽  
Ying Yang ◽  
Lajos Pusztai ◽  
...  
Keyword(s):  
Lymph Node ◽  
Protein Kinase ◽  
Breast Carcinoma ◽  
Prognostic Significance ◽  
Mitogen Activated Protein Kinase ◽  
Node Positive ◽  
Mitogen Activated Protein ◽  
Her 2 ◽  
Lymph Node Positive

Molecular Changes in Tamoxifen-Resistant Breast Cancer: Relationship Between Estrogen Receptor, HER-2, and p38 Mitogen-Activated Protein Kinase

2005 ◽  
Vol 23 (11) ◽  
pp. 2469-2476 ◽  
Author(s):  
M. Carolina Gutierrez ◽  
Simone Detre ◽  
Stephen Johnston ◽  
Syed K. Mohsin ◽  
Jiang Shou ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Protein Kinase ◽  
Tamoxifen Resistance ◽  
Mitogen Activated Protein Kinase ◽  
Clinical Samples ◽  
Strong Correlations ◽  
Mitogen Activated Protein ◽  
Her 2 ◽  
Tamoxifen Resistant

Purpose To evaluate growth factor receptor cross talk with the estrogen receptor (ER) in paired clinical breast cancer specimens and in a xenograft model before tamoxifen and at tumor progression as a possible mechanism for tamoxifen resistance. Methods Specimen pairs from 39 patients were tissue arrayed and stained for ER, progesterone receptor (PgR), Bcl-2, c-ErbB2 (HER-2), and phosphorylated (p) p38 mitogen-activated protein kinase (MAPK), p-ERK1/2 MAPK, and p-Akt. Xenograft MCF-7 tumors before and after tamoxifen resistance were assessed for levels of p-p38. Results Pretreatment, there were strong correlations between ER, PgR, and Bcl-2, and an inverse correlation between ER and HER-2. These correlations were lost in the tamoxifen- resistant tumors and replaced by strong correlations between ER and p-p38 and p-ERK. ER expression was lost in 17% of resistant tumors. Three (11%) of the 26 tumors originally negative for HER-2 became amplified and/or overexpressed at resistance. All ER-positive tumors that overexpressed HER-2 originally or at resistance expressed high levels of p-p38. In the pretreatment and tamoxifen-resistant specimens, there were strong correlations between p-p38 and p-ERK. In the tamoxifen-resistant xenograft tumors, like the clinical samples, there was a striking increase in p-p38. Conclusion The molecular pathways driving tumor growth can change as the tumor progresses. Crosstalk between ER, HER-2, p38, and ERK may contribute to tamoxifen resistance and may provide molecular targets to overcome this resistance.

scholarly journals Influence of the time between surgery and radiotherapy on local recurrence in patients with lymph node-positive, early-stage, invasive breast carcinoma undergoing breast-conserving surgery

Cancer ◽  
2005 ◽  
Vol 104 (2) ◽  
pp. 240-250 ◽  
Author(s):  
Mohamed Benchalal ◽  
Elisabeth Le Prisé ◽  
Brigitte de Lafontan ◽  
Dominique Berton-Rigaud ◽  
Yazid Belkacemi ◽  
...  
Keyword(s):  
Lymph Node ◽  
Breast Carcinoma ◽  
Local Recurrence ◽  
Early Stage ◽  
Breast Conserving Surgery ◽  
Invasive Breast Carcinoma ◽  
Node Positive ◽  
Lymph Node Positive

Impact of selected tumor and patient characteristics on outcome of lymph node-positive breast cancer patients.

2015 ◽  
Vol 33 (28_suppl) ◽  
pp. 66-66
Author(s):  
Ahmed Aly Nagy ◽  
Hager Ibrahim ◽  
Lamiaa Eid ◽  
Fatma Sayed ◽  
Mohamed Reda Kelany ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Cancer Patients ◽  
Tumor Size ◽  
Patient Characteristics ◽  
Breast Cancer Patients ◽  
Node Positive ◽  
Her 2 ◽  
Lymph Node Positive ◽  
Positive Breast Cancer

66 Background: Axillary lymph node (ALN) involvement remains the most significant factor affecting long term survival in breast cancer (BC) patients, and the risk of treatment failure is increased with the higher the number of ALN involvement, The aim of this study was to determine the impact of tumor characteristics; tumor size and number of positive lymph nodes and, ER and HER-2, as well as patient characteristics on DFS of patients with Lymph node positive Breast Cancer Patients who received Adjuvant Treatment. Methods: We retrospectively reviewed data of 704 patients with BC and ALN involvement who received adjuvant treatment in the period between 2010 and 2012. DFS outcomes were estimated with the Kaplan-Meier method and compared using the log rank test to determine. The effect of prognostic factors on BC outcomes. Results: Median age was 50 years (SD±12.024, Range 21-88). About 83.7% of the tumors were IDC,. About 30.4%of the tumors were grade III. Median tumor size was 5 cm (SD± 1.3745, Range 1-7).Median number of positive axillary LN was 4 (SD± 4.987, Range 1-37). Regarding receptor expression; 21.2% were HER-2 +ve, 58.7% were ER +ve and about 30.4 were triple negative. Median DFS was 20 months (SD± 14.511, Range 1-60). Cox regression showed that age, positive ER status and more than 3 ALN involvement had a statistically significant impact on DFS ( p<0.001 for all ), however, Tumor size, HER-2 overexpression, patient menstrual status had no significant effect. ER positive age >50 years was associated with prolonged DFS of 23 months (95%CI=20.641-25.359) versus 19 months (95% CI=17.598-20.402) for age≤50 years (p<0.001). ER positive status was associated with prolonged DFS of 22 months (95%CI=20.290-23.710) versus 17 months (95% CI=14.049-19.951) for ER negative (p<0.001).The group of patients with ≤3 positive dissected LN was associated with statistically significant prolonged DFS of 25 months (95%CI=22.286-27.714) versus 15 months (95%CI = 12.353-17.647) for patients with>3 positive dissected LN (p<0.001). Conclusions: These study indicate that the age, ER status and more than 3 ALN involvement have impact on DFS in Lymph node positive Breast Cancer Patients.

Sign in / Sign up

Export Citation Format

Share Document